SCHEDULE 13G/A: Citadel Entities Disclose Passive Stake in Protara Therapeutics, Inc.
Beneficial Ownership Disclosure
Citadel and its affiliates, including Kenneth Griffin, have disclosed a passive beneficial ownership stake of up to 4.7% in Protara Therapeutics, Inc. as of December 31, 2024.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 1,612,531 shares of Protara Therapeutics, Inc., representing 4.6% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 15,203 shares, representing 0.0% of the class.
- Kenneth Griffin, as the ultimate control person, beneficially owns 1,627,734 shares, representing 4.7% of the class.
- The percentages are calculated based on a total of 34,919,772 shares outstanding, which includes 20,629,772 shares as of November 7, 2024, 13,690,000 shares from a private placement, and 600,000 shares issuable upon exercise of certain warrants held by affiliates of the Reporting Persons.
- The filing indicates a passive investment purpose, stating the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. While a large investor's stake can be seen positively, the filing itself is purely informational and passive.
Positives
- The disclosure of a significant passive stake by a prominent investment firm like Citadel could be interpreted as a vote of confidence in Protara Therapeutics, Inc.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by a major investment firm in a publicly traded company. It does not provide specific insights into broader industry trends, but rather reflects an investment decision within the company's sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership by institutional investors, which can influence market perception and liquidity.
- Investment Professionals: Offers data points for tracking institutional ownership and potential investment trends.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date of shares outstanding reported in Protara Therapeutics' Form 10-Q. |
| 2024-11-12 | Date Protara Therapeutics' Form 10-Q was filed with the SEC. |
| 2024-12-11 | Date Protara Therapeutics' Prospectus for private placement was filed with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G/A statement. |
| 2025-02-14 | Date the Schedule 13G/A was signed by the Reporting Persons. |
Keywords
Protara Therapeutics, Citadel, Kenneth Griffin, SEC filing, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Passive Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.